Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS)....

Descripción completa

Detalles Bibliográficos
Autores principales: Siena, S, Peeters, M, Van Cutsem, E, Humblet, Y, Conte, P, Bajetta, E, Comandini, D, Bodoky, G, Van Hazel, G, Salek, T, Wolf, M, Devercelli, G, Woolley, M, Amado, R G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360255/
https://www.ncbi.nlm.nih.gov/pubmed/18040272
http://dx.doi.org/10.1038/sj.bjc.6604053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360255/
https://www.ncbi.nlm.nih.gov/pubmed/18040272
http://dx.doi.org/10.1038/sj.bjc.6604053

Ejemplares similares